Stavudine

CHEMBL991 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
224.2 g/mol
LogP
-0.8
Phase
4

An older antiretroviral nucleoside analogue that was widely used in early HIV treatment regimens by blocking the reverse transcriptase enzyme the virus needs to replicate. It has largely been replaced by better-tolerated alternatives due to its risk of causing peripheral nerve damage and serious metabolic complications with long-term use.

Berat Molekul

224,2100 g/mol

LogP

-0,80

TPSA

78,90 Ų

Lipinski RO5

Lulus

Area Terapeutik

Mekanisme Kerja

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O

InChI

InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

Molecular Formula

C10H12N2O4

HBD / HBA

2 / 4

Ikatan yang Dapat Dirotasi

2

Atom Berat

16

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An older antiretroviral nucleoside analogue that was widely used in early HIV treatment regimens by blocking the reverse transcriptase enzyme the virus needs to replicate. It has largely been replaced by better-tolerated alternatives due to its risk of causing peripheral nerve damage and serious metabolic complications with long-term use.

Inhibits viral reverse transcriptase, blocking the conversion of viral RNA to DNA and preventing viral replication in infected host cells.

Yes, Stavudine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL991. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 18283. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.